Bryan Edward Jones
20Patents
8h-index
47Co-inventors
75Inventor score
Filing activity: Dec 26, 1973 → Mar 31, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7632499B2 | Anti-myostatin antibodies | Chemistry; Metallurgy | 49 | Active |
| US7494651B2 | TGF-β binding antibodies | Chemistry; Metallurgy | 17 | Active |
| US7939494B2 | Method for administering GLP-1 molecules | Human Necessities | 16 | Active |
| US4274299A | Collapsible steering column | Performing Operations; Transporting | 14 | Expired |
| US6630138B2 | Protein C derivatives | Human Necessities | 14 | Expired |
| US8066995B2 | Anti-myostatin antibodies | Chemistry; Metallurgy | 9 | Active |
| US7927593B2 | TGF-beta binding antibodies | Chemistry; Metallurgy | 9 | Active |
| US4512938A | Undulating heat exchange packing | Emerging Cross-Sectional Technologies | 9 | Expired |
| US3989558A | Coating and diffusion process for improving the life of cobalt-bonded sintered carbide tools | Chemistry; Metallurgy | 5 | Expired |
| US4927174A | Steering column coupling | Emerging Cross-Sectional Technologies | 5 | Expired |
| US11370828B2 | Anti-coronavirus antibodies and methods of use | Physics | 3 | Active |
| US7204981B2 | Methods of treating diseases with activated protein C | Emerging Cross-Sectional Technologies | 3 | Expired |
| US6998122B1 | Protein C derivatives | Human Necessities | 1 | Expired |
| US7638123B2 | Methods of treating diseases with activated protein C | Emerging Cross-Sectional Technologies | 0 | Active |
| US10435479B2 | Chemically-locked bispecific antibodies | Chemistry; Metallurgy | 0 | Active |
| US8076298B2 | Treating acute renal failure with soluble thrombomodulin variants | Human Necessities | 0 | Active |
| US6841371B2 | Protein C derivatives | Emerging Cross-Sectional Technologies | 0 | Expired |
| US12172038B2 | Anti-coronavirus antibodies and methods of use | Physics | 0 | Active |
| US11447541B1 | Anti-coronavirus antibodies and methods of use | Physics | 0 | Active |
| US8492330B2 | Formulation comprising GLP-1 | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.